Anavo Tablet

About Anavo 1 mg Tablet

Anavo 1 mg Tablet is a medicine that helps prevent nausea and vomiting caused by cancer treatment or radiation. It belongs to a group of drugs that block a specific serotonin signal in the body.

There are 2 brands of Granisetron listed in Bangladesh. The lowest listed price is Naurif 1 mg Tablet at ৳ 28.19 per unit.

What is Anavo 1 mg Tablet?

Anavo 1 mg Tablet contains granisetron, a medicine that blocks serotonin signals in the body that trigger nausea and vomiting. It is used to prevent these symptoms in people receiving emetogenic cancer therapy, including high-dose cisplatin, and in those having radiation therapy such as total body irradiation or fractionated abdominal radiation. The tablet works by blocking certain receptors on nerve endings and in the brain area that controls vomiting. Your doctor will decide if this medicine is suitable for you and will determine the dose and course of treatment.

Uses of Anavo

Anavo 1 mg Tablet is used to prevent nausea and vomiting linked to initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. It is also used for nausea and vomiting associated with radiation therapy, including total body irradiation and fractionated abdominal radiation. It is a supportive care medicine given alongside cancer treatment. Your doctor will decide whether it is appropriate for your situation.

How to use Anavo

Take Anavo 1 mg Tablet exactly as your doctor tells you. The dose and timing depend on your treatment schedule. Swallow the tablet with water. Your doctor will decide how many tablets you need each day and when to take them in relation to your cancer therapy or radiation. Do not change the dose or stop the medicine without asking your doctor. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Anavo

Like all medicines, Anavo 1 mg Tablet can cause side effects. Common ones include headache, trouble sleeping, constipation, diarrhoea, and raised liver enzymes. Some people may experience changes in heart rhythm, slow heart rate, palpitations, or chest pain. Tell your doctor if you notice any side effects or if they bother you. Your doctor can advise on how to manage them.

Safety and precautions

Before taking Anavo 1 mg Tablet, tell your doctor if you have heart problems, are having cardiotoxic chemotherapy, or have electrolyte abnormalities. This medicine may hide signs of a bowel blockage or stomach swelling. It is pregnancy category B, but it should be used in pregnancy only if clearly needed. It is not known if granisetron passes into breast milk, so caution is needed in nursing mothers. Ask your doctor if you are pregnant or breastfeeding. Your doctor will decide if it is safe for you.

Frequently asked questions

What kind of medicine is Anavo 1 mg Tablet and what is it used for?

Anavo 1 mg Tablet is a supportive care medicine containing granisetron. It is used to prevent nausea and vomiting that can happen with cancer therapy, including high-dose cisplatin, and with radiation therapy such as total body irradiation or fractionated abdominal radiation.

Which medicines may interact with Anavo 1 mg Tablet?

Anavo 1 mg Tablet may interact with phenobarbital, medicines that affect serotonin such as SSRIs and SNRIs, drugs that alter certain liver enzymes, and medicines that prolong the QT interval. Tell your doctor or pharmacist about all medicines you take before starting Anavo.

Who should avoid Anavo 1 mg Tablet or ask the doctor first?

Do not take Anavo 1 mg Tablet if you are allergic to granisetron. Ask your doctor first if you have heart problems, electrolyte abnormalities, or are having cardiotoxic chemotherapy. Also ask if you are pregnant or breastfeeding, or if you have signs of bowel obstruction.

Can Anavo 1 mg Tablet be used in pregnancy or while breastfeeding?

Anavo 1 mg Tablet is in pregnancy category B and should be used in pregnancy only if clearly needed. It is not known if granisetron passes into breast milk, so caution is needed in nursing mothers. Ask your doctor to decide whether it is suitable for you.

Indications

Granisetron Tablet is indicated for Nausea and vomiting associated with initial and repeat course of emetogenic cancer therapy, including high dose of cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Granisetron ... Read moreGranisetron Tablet is indicated for Nausea and vomiting associated with initial and repeat course of emetogenic cancer therapy, including high dose of cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.

Granisetron Injection is indicated for: The prevention of nausea and vomitng associated with initial and repeat courses of emetogenic cancer chemotherapy, therapy including high dose cisplatin. The prevention and treatment of post operative nausea and vomiting.

Pharmacology

Granisetron is a highly selective 5-HT3 receptor antagonist with little or no affinity for other serotonin receptors. It blocks serotonin peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone.

Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.

In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG. No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in other studies.

Dosage & Administration

Tablet-

Emetogenic Chemotherapy: The recommended adult dosage of oral Granisetron is 2 mg once daily or 1 mg twice daily. In the 2 mg once-daily regimen, two 1 mg tablets is given up to 1 hour before chemotherapy. In the 1 mg twice-daily regimen, the first 1 mg tablet is given up to 1 hour before chemotherapy, and the second tablet is given 12 hours after the first. Either regimen is administered only on the day(s) chemotherapy is given. Continued treatment, while not on chemotherapy, has not been found to be useful.

Injection-

Chemotherapy Induced Nausea and Vomiting:
  • Adults: The recommended dosage for Granisetron Injection is 10 mcg/kg administered intravenously within 30 minutes before initiation of chemotherapy, and only on the day(s) chemotherapy is given. Granisetron Injection may be administered intravenously either undiluted over 30 seconds, or diluted with 0.9% Sodium Chloride or 5% Dextrose and infused over 5 minutes. As a general precaution, Granisetron Injection should not be mixed in solution with other drugs.
  • Paediatric Patients: The recommended dose in paediatric patients 2 to 16 years o f age is 10 mcg/kg. Paediatric patients under 2 years o f age have not beenstudied.
  • Geriatric Patients, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required.
Treatment of Postoperative Nausea and Vomiting:
  • Adults: The recommended dosage for prevention of postoperative nausea and vomiting is, a single dose of 1 mg of Granisetron should be diluted to 5 ml andadministered as a slow intravenous injection (over 30 seconds). Administration should be completed prior to induction of anesthesia. The recommended dosage for the treatment of nausea and vomiting after surgery is 1 mg of Granisetron undiluted, administered intravenously over 30 seconds.
  • Paediatric Patients: Safety and effectiveness of Granisetron Injection have not been established in paediatric patients for the prevention or treatment of post operative nausea or vomiting.
  • Geriatricpatients, Renal Failure Patients or Hepatically Impaired Patients: No dosage adjustment is required.

Interaction

Induced metabolism with phenobarbital. Risk of serotonin syndrome with other serotonergic agents e.g. SSRIs, and serotonin and norepinephrine reuptake inhibitors (SNRIs). Altered clearance with CYP enzyme inducers or inhibitors. Concomitant use with drugs known to prolong QT interval may result in clinical consequences.

Contraindications

Granisetron is contraindicated in patients with known hypersensitivity to granisetron.

Side Effects

Headache, insomnia, constipation, diarrhoea, elevated hepatic transaminases; QT prolongation; bradycardia, palpitations, sick sinus syndrome, chest pain. Application site reactions (transdermal): Rash, pain, erythema, pruritus, irritation, burn, vesicles, urticaria, discolouration; patch non-adhesion.

Pregnancy & Lactation

Pregnancy Category B. No evidence of impaired fertility or harm to the animal fetus have been found. However, this drug may be used in pregnancy only if clearly needed. It is not known whether granisetron is excreted in human milk. So cautions hould be exercised when granisetron is administered to a nursing mother.

Precautions & Warnings

Patient with cardiac co-morbidities, on cardiotoxic chemotherapy and/or woth concomitant electrolyte abnormalities. May mask progressive ileus and/or gastric distention. Childn. Pregnancy and lactation.

Storage Conditions

Store between 15-30°C. Protect from light.

Alternative brands of Granisetron

Other brands with the same generic name, cheapest first.

Naurif Tablet

1 mg

Granisetron

Square Pharmaceuticals PLC.

৳ 27.63 ৳ 28.19 2% off per unit

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.